Biorithm, a women’s health medtech company based in Cambridge, has secured $3.5 million in Series A funding to advance maternal care across the globe. The funding, co-led by Adaptive Capital Partners and SEEDS Capital, will support Biorithm’s expansion in Southeast Asia and the United States. It will also help the company develop Femom, a remote monitoring solution for obstetric care, and complete clinical studies for FDA premarket submission.
Biorithm aims to address preventable pregnancy complications by remotely monitoring maternal and fetal biometrics. The company’s Femom technology enables patient monitoring, personalized guidance and predictive analytics to help clinicians identify early signs of complications.
The company has already completed clinical trials in Singapore and the U.K. With its fresh capital, Biorithm plans to expand its clinical trial footprint to more priority markets and conduct further research on remote care deployment. It also aims to foster partnerships with stakeholders globally to further its goal of improving maternal and baby health through data-driven, personalized and accessible care.
